Picture of Cue Biopharma logo

CUE Cue Biopharma Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Momentum

Relative Strength (%)
1m-16.86%
3m-45.6%
6m-26.83%
1yr-63.22%
Volume Change (%)
10d/3m+7.16%
Price vs... (%)
52w High-69.53%
50d MA-20.66%
200d MA-39.7%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-117.32%
Return on Equity-98.73%
Operating Margin-949.89%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Cue Biopharma EPS forecast chart

Profile Summary

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
December 31st, 2014
Public Since
January 2nd, 2018
No. of Shareholders
86
No. of Employees
53
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
48,643,316

CUE Share Price Performance

Upcoming Events for CUE

Q1 2024 Cue Biopharma Inc Earnings Release

Cue Biopharma Inc Annual Shareholders Meeting

Q2 2024 Cue Biopharma Inc Earnings Release

Similar to CUE

Picture of 180 Life Sciences logo

180 Life Sciences

us flag iconNASDAQ Capital Market

Picture of Abeona Therapeutics logo

Abeona Therapeutics

us flag iconNASDAQ Capital Market

Picture of ABVC Biopharma logo

ABVC Biopharma

us flag iconNASDAQ Capital Market

Picture of Acesis Holdings logo

Acesis Holdings

us flag iconNASDAQ Capital Market

Picture of Achieve Life Sciences logo

Achieve Life Sciences

us flag iconNASDAQ Capital Market

FAQ